Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN): 'we'd be buyer on weakness'
Tweet Send to a Friend
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $95.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
